Synthon B.v.

Synthon IP Inc.

Gerrit J B Ettema

Faysal Kalmoua

Raymond J H Westheim

Jacobus Maria Lemmens

Lambertus Thijs

Rolf Keltjens

Korinde Annemarie Jansen

Hans Jan Hoorn

Farid Abedin Dorkoosh

Crystalline aripiprazole Type II can be formulated into pharmaceutical tablets having reduced dissolution profile variability upon storage.

Pharmaceutical tablets of crystalline type II aripiprazole

Crystalline aripiprazole Type II can be formed without solid state heat treatment. Instead a liquid is used such as in crystallizing from a solvent, especially 2-propanol, dimethyl sulfoxide, or a combination thereof with ethyl acetate, or in a solvent mediated solid-solid transformation, typically in ethyl acetate.

Process of making crystalline type II aripiprazole

Process of making crystalline Type II aripiprazole

Bicalutamide and/or its intermediates are made by the use of p-fluorobenzenesulfinic acid salt as a reagent.

Process for making bicalutamide and intermediates thereof

Amlodipine besylate forms are described, including amlodipine besylate hydrates and novel amlodipine besylate anhydrates. A method of making various amlodipine besylate forms from an aqueous medium as well as the use of the same as a calcium channel blocker are described.

Amlodipine salt forms and processes for preparing them

Amlodipine hemimaleate is useful as a calcium channel blocker and can be used to treat or prevent angina or hypertension.

Growing community of inventors

Nijmegen, Netherlands

Gerrit J B Ettema